预防性褪黑素治疗重症监护谵妄(Pro-MEDIC):随机对照试验研究方案
本研究为澳大利亚多中心、随机、安慰剂对照试验,计划纳入850例预期ICU停留≥72小时的成人患者,按1:1随机接受褪黑素4 mg肠内给药或安慰剂,每日21:00一次至出ICU或入组后14天,主要目的是确定预防性褪黑素能否降低谵妄发生率。
要点
- 多中心随机安慰剂对照试验,计划纳入850例成人ICU患者,褪黑素4 mg每日21:00肠内给药。
- 主要目的为确定预防性褪黑素较安慰剂能否降低谵妄发生率。
- 100例子组将接受多导睡眠监测以评估睡眠质量。
核心结论
- 本试验将确定预防性褪黑素用于危重成人较安慰剂能否降低谵妄发生率。
- 作者认为该试验将是危重人群预防谵妄中褪黑素规模最大的评估,并提供ICU内最大系列的多导睡眠监测之一。
研究设计与样本
- 多中心、随机、安慰剂对照研究,在澳大利亚封闭式ICU进行。
- 计划纳入850例预期ICU停留72小时或以上的成人患者,按计算机生成随机列表以1:1比例随机,按中心分层。
- 患者、医生、护士、研究者和统计师均设盲,研究药物与安慰剂不可区分。
主要发现
- 褪黑素4 mg或安慰剂每日21:00肠内给药一次,直至出ICU或入组后14天,以先发生者为准。
- 受训人员每日两次使用ICU意识模糊评估法评估谵妄是否存在。
- 收集人口学、谵妄总体患病率、谵妄持续时间和严重程度、睡眠质量、物理治疗参与、ICU和住院时间、发病率与死亡率及医疗费用等数据。
- 100例子组将接受多导睡眠监测以进一步评估睡眠质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delirium is an acute state of brain dysfunction characterised by fluctuating inattention and cognitive disturbances, usually due to illness. It occurs commonly in the intensive care unit (ICU), and it is associated with greater morbidity and mortality. It is likely that disturbances of sleep and of the day-night cycle play a significant role. Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep. The main aim of this trial will be to determine whether prophylactic melatonin administered to critically ill adults, when compared with placebo, decreases the rate of delirium. METHODS: This trial will be a multi-centre, randomised, placebo-controlled study conducted in closed ICUs in Australia. Our aim is to enrol 850 adult patients with an expected ICU length of stay (LOS) of 72 h or more. Eligible patients for whom there is consent will be randomised to receive melatonin 4 mg enterally or placebo in a 1:1 ratio according to a computer-generated randomisation list, stratified by site. The study drug will be indistinguishable from placebo. Patients, doctors, nurses, investigators and statisticians will be blinded. Melatonin or placebo will be administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first. Trained staff will assess patients twice daily to determine the presence or absence of delirium using the Confusion Assessment Method for the ICU score. Data will also be collected on demographics, the overall prevalence of delirium, duration and severity of delirium, sleep quality, participation in physiotherapy sessions, ICU and hospital LOS, morbidity and mortality, and healthcare costs. A subgroup of 100 patients will undergo polysomnographic testing to further evaluate the quality of sleep. DISCUSSION: Delirium is a significant issue in ICU because of its frequency and associated poorer outcomes. This trial will be the largest evaluation of melatonin as a prophylactic agent to prevent delirium in the critically ill population. This study will also provide one of the largest series of polysomnographic testing done in ICU. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry (ANZCTR) number: ACTRN12616000436471 . Registered on 20 December 2015.
引用
- Martinez FE, Anstey M, Ford A, et al. Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial. Trials. 2017. PMID: 28061873. doi:10.1186/s13063-016-1751-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。